{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:inotropes-and-vasopressors",
  "owner": "cardio",
  "kind": "drug",
  "slug": "inotropes-and-vasopressors",
  "name": "Inotropes and vasopressors",
  "aliases": [
    "Inotropic agents",
    "Positive inotropes",
    "Cardiotonic agents",
    "Vasopressor agents",
    "Vasoconstrictor agents"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Inotropes are medicines that strengthen the heart, and vasopressors are medicines that narrow blood vessels. MeSH describes cardiotonic agents as agents that strengthen the heart or increase cardiac output, and vasoconstrictor agents as drugs that constrict blood vessels. US labels call dobutamine an inotropic agent, milrinone a positive inotrope and vasodilator, and norepinephrine a peripheral vasoconstrictor and an inotropic stimulator of the heart. This is the class page.",
  "summary_technical": "Class page. Two MeSH descriptors, both broad matches because each covers only half of the page: D002316 (Cardiotonic Agents, strengthening effect on the heart or increased cardiac output, named uses after myocardial infarction and cardiac surgery, in shock and in heart failure) and D014662 (Vasoconstrictor Agents, drugs used to cause constriction of the blood vessels). Vasopressor Agents is a MeSH entry term of the second (read 2026-11-18, hash only). The three members are filed by label wording, not by RxClass: the labels read (Hikma milrinone lactate, ANDA077966; Baxter dobutamine in dextrose, NDA020255; Hospira Levophed, NDA007513) call the products a positive inotrope, an inotropic agent and an inotropic stimulator of the heart, and RxClass gives them three different pharmacologic classes (Phosphodiesterase 3 Inhibitor, beta-Adrenergic Agonist and Catecholamine), none of which is named for the inotrope effect. The milrinone label says milrinone differs in structure and mode of action from the digitalis group and from the catecholamines, so the class groups by effect, not by chemistry. The Levophed label lists raising blood pressure in adults with severe, acute hypotension. Statements are scoped to the labels read. No trial result and no dose is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": "2027-05-18",
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D002316",
      "normalized_value": "D002316",
      "match": "broad",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D014662",
      "normalized_value": "D014662",
      "match": "broad",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart",
        "blood-vessels"
      ],
      "condition-area": [
        "heart-failure",
        "acute-care-and-long-term-living"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "The labels read describe a positive inotrope and vasodilator (milrinone), an inotropic agent acting on the beta-receptors of the heart (dobutamine) and a peripheral vasoconstrictor that is also an inotropic stimulator of the heart (norepinephrine)."
  },
  "content_digest": "993998e64694dfbd469046da6c7a7fcc3e09bf4b4f3735087c4bafb9146d1493",
  "review": {
    "content_digest": "993998e64694dfbd469046da6c7a7fcc3e09bf4b4f3735087c4bafb9146d1493",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MeSH names heart failure among the uses of cardiotonic agents",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:heart-failure",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MeSH names shock among the uses of cardiotonic agents; cardiogenic shock is one kind of shock",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:cardiogenic-shock",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "related_to",
        "label": "Related to",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:cardiac-glycosides-digoxin",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:dobutamine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-6b17b98b-e06d-42ed-925f-69aa2699dead-2026-11-08",
          "locator": "results[0].clinical_pharmacology[0]"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:milrinone",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-88f78780-399f-4780-be19-205739db1682-2026-11-08",
          "locator": "results[0].clinical_pharmacology[0]"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:norepinephrine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-c4de72a8-2a75-4984-ce90-e4870226dc12-2026-11-08",
          "locator": "results[0].mechanism_of_action[0]"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/inotropes-and-vasopressors/",
  "context_path": "api/v1/context/cardio--inotropes-and-vasopressors.md"
}
